Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin Peptides

Abstract

The resolution of inflammation is now known to be an active process, armed with a multitude of mediators both lipid and protein in nature. Melanocortins are peptides endowed with considerable promise with their proresolution and anti-inflammatory effects in preclinical models of inflammatory disease, with tissue protective effects. These peptides and their targets are appealing because they can be seen as a natural way of inducing these effects as they harness endogenous pathways of control. Whereas most of the information generated about these mediators derives from several acute models of inflammation (such as zymosan induced peritonitis), there is some indication that these mediators may inhibit chronic inflammation by modulating cytokines, chemokines, and leukocyte apoptosis. In addition, proresolving mediators and their mimics have often been tested alongside therapeutic protocols, hence have been tested in settings more relevant to real life clinical scenarios. We provide here an overview on some of these mediators with a focus on melanocortin peptides and receptors, proposing that they may unveil new opportunities for innovative treatments of inflammatory arthritis.

Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial

“…Results from preclinical studies suggest several nonsteroidogenic pathways for RCI that may affect inflammation and immune regulation. Activation of MCR1 has been shown to affect the nuclear factor-jB (NF-jB) pathway, leading to downregulation of inflammatory cytokines [11][12][13]. Multiple cells of the immune system express MCR1, MCR3, and/or MCR5, suggesting they have additional roles in mediating inflammation [11,14,15].…”

Effect of BMS-470539 on lipopolysaccharide-induced neutrophil activation

“…MC1Rs are primarily located on the surface of melanocytes, which produce a pigment called melanin. MC1Rs have been also detected on various immune cells other than melanocyte, including neutrophils, monocytes, and dendritic cells [3][4][5]. Although the active functions of MC1R in immune cells, especially for neutrophils, have not been previously elucidated in detail, including the signaling pathway and impact on cell survival, some preclinical investigations indicate activation of MC1R could be a new strategy to control inflammatory disorders with a collective reduction of the major molecules involved in the inflammatory process.…”

Immunoglobulin A Nephropathy: Advances in Understanding of Pathogenesis and Treatment

“…The melanocortin receptor pathway is one example of a process that can be regulated to decrease the inflammation in these conditions [59] and, as this pathway is also well developed in the kidney, it offers a potential target in proteinuric nephropathies, including IgA nephropathy. In addition, as immunosuppressive agents are being investigated for their general immunomodulatory effects, it is noteworthy that they may also have potential direct effects at receptors in the podocyte.…”